Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Universal Health Coverage Day 2018

 
Universal Health Coverage Day 2018
Unite for Universal Health Coverage: Now is the Time for Collective Action

http://www.emro.who.int/media/news/universal-health-coverage-day-2018.html

12 December 2018, Cairo ‒ Universal Health Coverage (UHC) Day, commemorated each 12 December, is the anniversary of the first unanimous United Nations resolution calling for countries to provide affordable, quality health care to every person, everywhere.

“UHC is a simple idea: that everyone should be able to access the health services they need, without suffering financial hardship. Globally, we have a lot of work to do to realise that dream,” said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO).

“At least half of the world's population cannot access essential services like vaccination, essential medicines, or the ability to see a health worker. And every year, nearly 100 million people are pushed into extreme poverty due to out-of-pocket health spending.”

In the WHO Eastern Mediterranean Region, around 40% of health expenditure comes directly from people’s pockets, and most people cannot afford it. People with low incomes and without social protection are the hardest hit. As a result, an estimated 7.5 million people are pushed into poverty every year in the Region due to spending on health.

UHC has a special relevance to people living in countries with acute and prolonged emergency situations, and therefore for the Region, given that half of the world’s internally displaced populations are living in countries of the Region and more than 60% of the world’s refugees and migrants originate from the Region.

Vision 2023, developed by Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean, to guide the Organization’s work, acknowledges the socioeconomic diversity, opportunities and challenges facing the Region and calls for solidarity and action to promote “Health for All by All”. In line with WHO’s Thirteenth General Programme of Work 2019–2023, Vision 2023 has identified expanding UHC as a top strategic priority for the Region, and focuses on implementing the recommendations of the Salalah Declaration on UHC of September 2018 to ensure that at least 100 million more people benefit from UHC by 2023.

“Vision 2023 is a renewed call to aspire to the goal of Health for All, but it also stresses that Health for All can only be achieved by All. To move towards UHC, we need to engage everyone – governments, parliaments, academic and professional institutions, nongovernmental organizations, our sister United Nations agencies, communities, civil society and individuals – as proactive agents for change,” said Dr Al-Mandhari.

“I am glad that the theme for UHC Day 2018 is in harmony with our vision of Health for All by All. We shall all unite for UHC. Now is the time for collective action.”

Ministers of health and heads of delegations from the countries of the Region have recently collectively signed the UHC2030 Global Compact, making the Region the first among WHO’s six regions to do so. The signing of the UHC2030 Global Compact demonstrates a high level of commitment to take action and make progress towards UHC by the countries of the Region. Furthermore, WHO’s Regional Committee for the Eastern Mediterranean in its 65th Session this year endorsed a resolution urging Member States to formulate a national vision for UHC and a roadmap towards its realization, taking into account country-specific health system challenges, the economic situation and people’s preferences.

The essence of UHC is the provision of an essential package of health services to the whole population and ensuring that those who cannot pay for health care are financially protected through prepayment schemes. Every country can make progress towards UHC, even low-income countries and those affected by emergencies. 

“Providing a basic package of health services for all, and then employing progressive universalism by building on this package as more resources become available, is the way to go about it”, said Dr Zafar Mirza, Director, Health System Development at the WHO Regional Office for the Eastern Mediterranean.
    ...
    15
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AA27 GILENYA B Fingolimod - 0.5mg 0.5mg Capsule 159,392,560 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 20mg 20mg Injectable powder for suspension+diluent L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 2mcg/ml 2mcg/ml Injectable solution 2,218,684 L.L
D10AD06 AKLIEF B Trifarotene - 50mcg/g 50mcg/g Cream 4,359,425 L.L
J07BK01 VARIVAX B Varicella virus, live attenuated - 1350PFU Injectable powder for suspension+diluent 4,102,751 L.L
L01EM03 PIQRAY B Alpelisib - 150mg 150mg Tablet, film coated 359,195,954 L.L
R03AK06 SERETIDE DISKUS 500 B Salmeterol (xinafoate) - 50mcg/inhalation, Fluticasone propionate - 500mcg/inhalation Inhalation powder 3,199,689 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 30mg 30mg Injectable powder for suspension+diluent L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 2mcg/ml 2mcg/ml Injectable solution 4,219,665 L.L
L01EM03 PIQRAY B Alpelisib - 200mg, Alpelisib - 50mg 150mg Tablet, film coated 359,195,954 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 1mcg 1mcg Capsule 3,735,882 L.L
J07BM03 GARDASIL 9 HUMAN PAPILLOMAVIRUS 9- VALENT VACCINE RECOMBINANT B Papillomavirus (human type 6) - 30mcg/0.5ml, Papillomavirus (human type 11) - 40mcg/0.5ml, Papillomavirus (human type 16) - 60mcg/0.5ml, Papillomavirus (human type 18) - 40mcg/0.5ml, Papillomavirus (human type 31) - 20mcg/0.5ml, Papillomavirus (human type 33) - 20mcg/0.5ml, Papillomavirus (human type 45) - 20mcg/0.5ml, Papillomavirus (human type 52) - 20mcg/0.5ml, Papillomavirus (human type 58) - 20mcg/0.5ml Injectable suspension 14,139,396 L.L
L01EM03 PIQRAY B Alpelisib - 200mg 200mg Tablet, film coated 359,195,954 L.L
R06AX29 LABIXTEN B Bilastine - 20mg 20mg Tablet 584,571 L.L
A08AA01 LOMAIRA B Phentermine Hydrochloride - 8mg 8mg Tablet 6,138,673 L.L
B02BX01 DICYNONE B Etamsylate - 250mg/2ml 250mg Injectable solution 482,439 L.L
J01DC02 ZINNAT B Cefuroxime (axetil) - 250mg 250mg Tablet, film coated 349,399 L.L
J07BX05 ABRYSVO B RSV subgroup A stabilized perfusion F antigen 60mcg - 60mcg, RSV subgroup B stabilized perfusion F antigen 60mcg - 60mcg, Glycoprotein F stabilized in the perfusion conformation - Injectable powder + solvent 22,650,721 L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule 54,006,801 L.L
N04BB01 PK-MERZ B Amantadine (sulfate) - 100mg 100mg Tablet, film coated 1,382,814 L.L
R06AX29 LABIXTEN B Bilastine - 2.5mg/ml 2.5mg/ml Solution 463,626 L.L
L02BA03 FASLODEX B Fulvestrant - 250mg/5ml 250mg/5ml Injectable solution L.L
A08AA62 CONTRAVE B Naltrexone Hydrochloride - 8mg, Bupropion Hydrochloride - 90mg Tablet, prolonged release 11,653,550 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.25mcg 0.25mcg Capsule 1,138,235 L.L
B02BX01 DICYNONE B Etamsylate - 500mg 500mg Capsule 1,311,590 L.L
C09CA06 ATACAND B Candesartan cilexetil - 8mg 8mg Tablet 526,786 L.L
J01DC02 ZINNAT B Cefuroxime (axetil) - 250mg/5ml 250mg/5ml Granules for suspension 1,120,782 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet 80,685,473 L.L
M01AG01 PONSTAN FORTE B Mefenamic acid - 500mg 500mg Tablet, film coated 219,046 L.L
    ...
    15
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025